Understand AV Nodal Reentrant Tachycardia (AVNRT) diagnosis, clinical features, and medical coding. Learn about AVNRT treatment, including catheter ablation, and find information on documentation for healthcare professionals. Explore resources for Atrioventricular Nodal Reentrant Tachycardia and improve your clinical understanding of this common supraventricular tachycardia.
A rapid heart rate originating from a reentrant circuit within the atrioventricular node.
Sudden onset palpitations, rapid pulse, dizziness, lightheadedness, shortness of breath, chest discomfort.
Emergency room, cardiology clinic, during or after exercise.
Complete code families applicable to I47.1
| Description | When to use |
|---|---|
| Fast heart rate starting in the AV node. | Use AVNRT or AV Nodal Reentrant Tachycardia when EKG confirms. Most common SVT. |
| Fast heart rate involving an extra pathway. | Use AVRT (Atrioventricular Reentrant Tachycardia) if EKG shows delta wave suggesting WPW. |
| Fast heart rate originating in the atria. | Use Atrial Tachycardia when EKG shows P waves before each QRS, distinct from sinus tachycardia. |
Miscoding AVNRT (I47.1) as AVRT (I47.2) due to similar names and abbreviations, impacting reimbursement and quality metrics.
Lack of documentation specifying typical or atypical AVNRT can lead to coding errors and affect clinical pathway selection.
Concurrent arrhythmias may be overlooked when coding AVNRT, leading to inaccurate reporting of comorbidities and complexity.
Verify sudden onset, regular, narrow-QRS tachycardia ECG
Confirm HR 120-250 bpm, P waves often buried in QRS
Assess symptoms: palpitations, dizziness, lightheadedness
Check response to vagal maneuvers or adenosine
Patient presents with a primary complaint of sudden onset palpitations, described as a rapid, regular heartbeat. Symptoms include shortness of breath and lightheadedness, but no syncope or chest pain. Electrocardiogram (ECG or EKG) reveals a narrow complex tachycardia with a regular rhythm, consistent with atrioventricular nodal reentrant tachycardia (AVNRT or AV nodal reentrant tachycardia). The heart rate is documented at 160 beats per minute. No discernible P waves are observed. The patient's medical history is significant for anxiety but negative for structural heart disease. Differential diagnoses considered include sinus tachycardia, atrial fibrillation, and atrioventricular reciprocating tachycardia (AVRT). Vagal maneuvers, specifically carotid sinus massage, were attempted and successfully terminated the tachycardia. Following conversion to normal sinus rhythm, the ECG showed normal sinus rhythm with a heart rate of 70 beats per minute. The patient reports complete resolution of symptoms. Diagnosis of AVNRT is confirmed. The patient was educated on AVNRT, including triggers, symptoms, and management strategies. Outpatient follow-up with cardiology is scheduled for further evaluation and consideration of long-term management options, including lifestyle modifications, medication, and potential radiofrequency ablation. Current treatment plan includes patient education and monitoring. ICD-10 code I47.1, Paroxysmal supraventricular tachycardia, is assigned.
Differentiating AVNRT from AVRT on an ECG can be challenging, but focusing on key features can aid accurate diagnosis and guide treatment. In AVNRT, the P wave is typically retrograde and often buried within the QRS complex or appears just after it, resulting in a pseudo-R' in V1. AVRT, however, usually presents with a visible retrograde P wave before, during, or after the QRS complex, depending on the specific pathway. The RP interval is also crucial; a short RP interval (<70ms) suggests AVNRT, while a longer RP interval is more indicative of AVRT. Furthermore, assessing the onset and offset of the tachycardia can provide clues. AVNRT often initiates and terminates suddenly, whereas AVRT may exhibit a more gradual onset or offset. Consider implementing a systematic approach using these ECG criteria to enhance diagnostic accuracy and tailor treatment accordingly. Explore how advanced electrophysiological studies can provide definitive diagnosis when surface ECG findings are inconclusive.
For stable patients presenting to the ED with AVNRT, vagal maneuvers, such as the Valsalva maneuver or carotid sinus massage (performed with caution and appropriate monitoring), are often the first-line treatment. If vagal maneuvers are unsuccessful, adenosine is the preferred pharmacological agent. Administering adenosine rapidly, followed by a saline flush, is crucial for its efficacy. Other options include intravenous calcium channel blockers (e.g., verapamil or diltiazem) or beta-blockers (e.g., metoprolol). Closely monitor the patient's heart rate, blood pressure, and oxygen saturation throughout the acute management phase. Learn more about the potential complications of these treatments and the criteria for considering alternative approaches like synchronized cardioversion if the patient becomes unstable.
Catheter ablation is the definitive treatment for AVNRT, offering high success rates exceeding 95% with low complication rates. During the procedure, radiofrequency energy is used to ablate the slow pathway within the AV node, effectively eliminating the reentrant circuit responsible for the tachycardia. While generally safe, potential complications include AV block, hematoma formation, and cardiac perforation, although these are rare. Discuss the risks and benefits of catheter ablation with your patients, emphasizing its high success rate and low risk profile. For patients who decline or are not suitable candidates for ablation, long-term medical therapy with beta-blockers, calcium channel blockers, or other antiarrhythmic medications can be considered. Explore how shared decision-making can empower patients to choose the most appropriate long-term management strategy based on their individual circumstances and preferences.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.